Fennec Pharmaceuticals Inc has seen a slight dip this week despite recent positive financial news.
Fennec Pharmaceuticals Inc (FRX.TO) closed at C$14.79, remaining unchanged on the day but down 3.46% for the week. The company recently reported strong financial results, indicating a positive trajectory for its flagship product, PEDMARK®.
Advertisement
Earn cash back with a smarter spending account
Open a KOHO account and start earning on everyday purchases — no annual fee on the base plan.
Fennec Pharmaceuticals Inc
FRX.TO
FRX.TO
Fennec Pharmaceuticals Inc
WealthAwesomeMarket cap
$484.58M
52W high
$15.48
52W low
$7.59
1W change
-0.72%
Beta
1.07
Analyst Price Targets
Based on analyst covering FRX
Wall Street analysts forecast FRX stock price to rise 575.6% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$93.57
+575.6% Upside
Current Price
C$13.85
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on FRX's historical volatility
30-Day Vol
48.5%
Annualized
90-Day Vol
82.5%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$16.56
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$14.70 | C$12.44 – C$17.37 |
| 60 trading days | C$15.60 | C$12.32 – C$19.76 |
| 90 trading days | C$16.56 | C$12.39 – C$22.12 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Despite its recent price dip, Fennec Pharmaceuticals continues to demonstrate growth in product sales and financial stability, which may appeal to long-term investors.
Fennec Pharmaceuticals Reports Record Annual Revenue of $44.6 Million
The company achieved a 50% year-over-year growth in net product sales, suggesting strong demand for its products.
Bull case
Fennec Pharmaceuticals reported record annual revenues and notable growth in product sales. This suggests a strong market position and potential for future profitability.
Bear case
The stock has declined recently, and its negative profit margins and return on equity (ROE) may raise concerns for risk-averse investors.
Recent Price Action
Advertisement
Fennec Pharmaceuticals Inc (FRX.TO) closed at C$14.79 on Wednesday, with no change from the previous day. Over the past week, the stock has experienced a decline of 3.46%. However, it has shown a significant increase of 19.27% over the past month and a remarkable 42.07% year-to-date performance.
Company News and Financial Performance
Fennec Pharmaceuticals recently announced record annual revenue, with net PEDMARK® product sales reaching $44.6 million, marking a 50% increase year-over-year. The fourth quarter of 2025 also saw a significant jump in sales, up 75% compared to the previous year. The company completed an oversubscribed equity offering, raising $42 million, and reported positive topline results from a clinical study of PEDMARK® in Japan. These developments highlight Fennec's growth trajectory and commitment to expanding its market presence.
Technical Picture
In terms of technical analysis, Fennec Pharmaceuticals is currently trading above both its 50-day moving average of C$12.82 and its 200-day moving average of C$11.29, indicating a bullish trend in the medium to long term. The stock has a beta of 1.07, suggesting it is slightly more volatile than the broader market. The 52-week range for FRX.TO is C$7.59 to C$15.48, with the current price sitting at approximately 91% of this range. However, the recent trading volume of 286 shares is significantly lower than the 20-day average volume of 1,531 shares, indicating reduced investor interest in the short term.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
